News

News 07.07.2020 Zurich-Schlieren, Switzerland, July 7, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built proteins known asDARPin® therapeutics, today announced that it has successfully placed 5,528,089 registered shares (the New Shares), corresponding to approximately 25% of the company's currently registered share capital,...

News 03.07.2020 Zurich-Schlieren, Switzerland, July 1, 2020. The shareholders of the company elected today Dr. Daniel L. Vasella, – former CEO and President of NOVARTIS - as new members to the Board of Directors of Topadur Pharma AG. “I am extremely happy with the election of Dr. Vasella to the Board of Directors....

News 26.06.2020 NORTH CHICAGO, Ill., June 26, 2020 – Allergan, an AbbVie Company (NYSE: ABBV), and Molecular Partners (SIX: MOLN), a clinical-stage biotechnology company developing a new class of custom-built protein therapeutics known as DARPin® therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter to the Biologics License...

News 19.06.2020 Schlieren, Switzerland – June 18, 2020   InSphero AG, the pioneer of 3D cell-based assay technology, today announced that the company will relocate its corporate headquarters and research and bioproduction laboratories to a larger facility in the Bio-Technopark Schlieren-Zürich life sciences building complex, positioned in the heart of the greater Zürich biotechnology hub....

News 08.06.2020 Zurich, Switzerland, June 4 2020 – CUTISS AG, an innovative Swiss Life Science Company aiming to provide patients that suffer from large and deep skin defects with an automatically produced, personalized skin tissue therapy, denovoSkin™, today announced it has successfully secured its series B financing round. Funds raised so far...